I thought id bring this company to the attention of people, its is HIGHLY HIGHLY undervalued. Trading at below net book, below net cash (.07).
Biotech company trading at .03 with 2 phase 2 trails, with cash for 3 years without needing a loan.
It has a partnership with Immune Pharm (which just recently IPO-ed) on their ico-008 for bullous pemphigoid.

If it is positive bullos pemphigoid research will gain orphan drug status (when the apply), making the profit even higher. It is a very unmet area. The science is also there. The only reason its trading at .03 is bc of lack of peoples patients, who have dumped it to play something else. Volume is ALSO VERY VERY thin, and ready for a volume crunch when the stock moves up. Lots of insider buys and immune pharm buys

cash and book..we trade at .07
actual market price/volume crunch at .15
positive on ico-008 at .25
take prive by immune pharm/buying of license at .30

currently trades at .03, makes no sense to me